Results: 28 patients were included: 78.5% male and 21.5% female. The main cause of portal hypertension was NASH (28.5%), followed by alcohol. There were 10 patients (35.8%) in Child A; (32.1%) in B, and (32.1%) in C. The MELD mean was 15.1. Only (10.7%) presented with severe thrombocytopenia. Splenomegaly was present in (46.4%), with portal dilation in (39.3%). In (78.5%) there was concomitant portal gastropathy. (39.3%) were performed in a context of high bleeding and (100%) were large.

Conclusion: No determining clinical parameters were found in relation to the presence of esophageal varices.

TableDistribution of patients.

28
31
3
2
35.7
64.3
39.3
58.2
78.5
21.5
15.1
35.8
32.1
32.1
28.5
39.3
10.7
21.5
39.3
17.8
46.4
100

https://doi.org/10.1016/j.aohep.2021.100435

P-73 HEPATIC CHANGES BY SARS-COV 2 IN PATIENTS OF THE INTENSIVE CARE UNIT OF THE TROPICAL MEDICINE CENTER IN RONDÔNIA

Camylla Felix Soares¹, Júlia Teixeira Ton², Luana Kamila Castilho Rodrigues¹, Stella Ângelo Zimmerli^{1,3}, Mariana Pinheiro Alves Vasconcelos¹

Introduction: Coronavirus (SARS-CoV2) infection occurs through the receptor's angiotensin converting enzyme 2, present in the pulmonary, biliary, and hepatic epithelial cells. Therefore, the liver is a potential target for infection.

Objectives: To analyze liver changes resulting from Sars-Cov-2 infection in patients admitted to the Intensive Care Unit of the Rondônia Tropical Medicine Center (CEMETRON).

Methods: Patients admitted between April and August 2020 in the CEMETRON ICU were included in the study. Project approved by the Research Ethics Committee. For statistical analysis, the SPSS® program was used.

Results: 307 patients were admitted to the CEMETRON ICU. 81 (26.4%) non-COVID and 226 (73.6%) diagnosed with COVID. Among the 226 tested positive for COVID, 52.3% and 54.3% had, respectively, an increase in ALT and AST up to three times the upper limit of

normal (40-120U/L). Non-COVID patients showed this increase in 20.8% for ALT and 33.3% for AST, being statistically significant (p: <0.005 for both). Transaminases above 120U/L had no statistically significant difference between the two groups. Regarding liver function assessed through bilirubin, albumin and platelets, there was no statistically significant difference in any of the variables (p: 0.93 p: 0.45 p: 0.599 respectively). The means varied within the normal range, except for both groups there was a tendency towards hypoalbuminemia (3.1 g / dL).

Conclusion: Patients with COVID evolved in more than 50% of the cases with changes in liver enzymes, showing that despite the inflammation, liver function was not directly affected. We associate hypoalbuminemia more with basal malnutrition than with hepatic impairment.

https://doi.org/10.1016/j.aohep.2021.100436

P-74 ELEVATED CALPROTECTIN LEVELS ARE ASSOCIATED WITH MORTALITY IN PATIENTS WITH ACUTE DECOMPENSATION OF CIRRHOSIS

Camila Matiollo¹, Elayne Cristina de Moraes Rateke¹, Emerita Quintina de Andrade Moura¹, Michelle Andrigueti¹, Fernanda Cristina De Augustinho², Tamara Liana Zocche², Telma Erotides da Silva², Lenyta Oliveira Gomes³, Mareni Rocha Farias³, Janaína Luz Narciso-Schiavon², Leonardo de Lucca Schiavon²

Introduction: Acute decompensation (AD) of cirrhosis is associated with systemic inflammation and increased circulating cytokines. The use of inflammatory markers, such as calprotectin, could provide information on the role of the immune response in the prognosis of cirrhosis.

Aims: To evaluate serum calprotectin levels in patients hospitalized complications of cirrhosis.

Methods: This prospective cohort study included 200 adult subjects hospitalized for complications of cirrhosis who were followed for up to 30 days after admission. Twenty healthy subjects and 20 patients with stable cirrhosis were evaluated as controls. Serum calprotectin was measured by the ELISA.

Results: Serum calprotectin levels were higher among the two groups of cirrhosis patients when compared to healthy controls. Greater median values of calprotectin were observed among patients with Child-Pugh C, ACLF, infection, ascites and hepatic encephalopathy. Concentrations of calprotectin were not related to the presence of ACLF, infection or to 30-days survival. However, when considered only patients with AD without ACLF (n = 144), higher values of calprotectin and CLIF-C ADs were associated with the lower survival in the univariate and multivariate Cox analyzes. The Kaplan-Meier survival probability was 98.7% in subjects with none of the factors (CLIF-C ADs <60 and calprotectin < 580 ng/mL), 83.6% in subjects with one of the factor (CLIF-C ADs ≥ 60 and calprotectin < 580 ng/mL or CLIF-C ADs < 60 and calprotectin \geq 580 ng/mL) and 27.3% in subjects with both factors (CLIF-C ADs \geq 60 and calprotectin \geq 580 ng/mL), in which p = 0.002 between the first and second groups, and p < 0.001between the first and third, and between the second and third groups (Figure).

¹ Centro Universitário São Lucas — UNISIL, Porto Velho, Rondônia

² Centro Universitario Aparicio Carvalho – UNIFIMCA, Porto Velho, Rondônia

³ Centro de Medicina Tropical de Rondônia – CEMETRON, Porto Velho, Rondônia

¹ Unidade de Laboratório de Análises Clínicas, Hospital Universitário, Universidade Federal de Santa Catarina

² Divisão de Gastroenterologia, Universidade Federal de Santa Catarina

³ Centro de Ciências da Saúde, Universidade Federal de Santa Catarina